Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/NMPA/Sitagliptin and Metformin Hydrochloride Sustained-release Tablets（Ⅱ）

Approved

化学药品

Sitagliptin and Metformin Hydrochloride Sustained-release Tablets（Ⅱ）

江苏宣泰药业有限公司🇨🇳 National Medical Products Administration

Approval Date: Dec 29, 2023
Approval ID: 8TCmleKLDtc
Company: 江苏宣泰药业有限公司
Type: 化学药品

Approval Details

Approval Id: 8TCmleKLDtc
Approval Number: 国药准字H20233644
Generic Name: 西格列汀二甲双胍缓释片(Ⅱ)
Generic Name En: Sitagliptin and Metformin Hydrochloride Sustained-release Tablets（Ⅱ）
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 每片含磷酸西格列汀50mg（以C₁₆H₁₅F₆N₅O计）和盐酸二甲双胍1000mg
Reg Date: 2023-12-29
Company Name: 江苏宣泰药业有限公司
Company Address: 南通市海门区滨江街道珠海路163号
Production Company Name: 江苏宣泰药业有限公司
Production Company Address: 南通市海门区滨江街道珠海路163号
Company Detail Path: /organization/5ba7f8e683bbd650/jiang-su-xuan-tai-yao-ye-you-xian-gong-si
Production Company Detail Path: /organization/5ba7f8e683bbd650/jiang-su-xuan-tai-yao-ye-you-xian-gong-si

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Dec 29, 2023

Approval ID

8TCmleKLDtc

Type

化学药品

Back to NMPA Approvals

西格列汀二甲双胍缓释片(Ⅱ) - NMPA Drug Approval Details